ACQUISITIONS AND TRANSACTIONS (Details 2)

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

Jun. 30, 2011

USD ($)

Jun. 30, 2011

USD ($)

Dec. 31, 2010

USD ($)

Jun. 30, 2010

USD ($)

Dec. 31, 2009

USD ($)

Jun. 30, 2011

Alba Therapeutics Corporation

USD ($)

Feb. 28, 2011

Alba Therapeutics Corporation

USD ($)

Feb. 09, 2011

Alba Therapeutics Corporation

USD ($)

Jun. 30, 2011

SymBio Pharmaceuticals Limited

Feb. 28, 2011

SymBio Pharmaceuticals Limited

USD ($)

Feb. 28, 2011

Mesoblast Limited

USD ($)

Feb. 28, 2011

Mesoblast Limited

AUD

Dec. 31, 2010

Mesoblast Limited

USD ($)

Jun. 30, 2011

Mesoblast Limited

USD ($)

Jun. 30, 2011

Mesoblast Limited

AUD

Jun. 30, 2011

Mesoblast Limited

USD ($)

Dec. 31, 2010

Mesoblast Limited

AUD

Mar. 31, 2011

Mepha GmbH

USD ($)

Jun. 30, 2011

United States

USD ($)

Dec. 31, 2010

United States

USD ($)

Acquisitions and transactions

Upfront option payment made under the terms of the option agreement

$ 7,000,000

Stock price (in dollars per share)

$ 79.90

$ 61.72

Stock price of the acquiree (in dollars per share)

5.57

8.65

4.67

Credit facility provided under the terms of the option agreement

22,000,000

Purchase price of assets if the entity exercises the option under the option agreement

15,000,000

Loans provided under the credit facility

10,000,000

Loss recognized on deconsolidation if the option expires unexercised

7,000,000

Purchase price of additional common shares

9,400,000

Percentage interest held in cost basis investment (as a percent)

18.50%

Nonrefundable up front payment agreed to be paid as part of a development and commercialization agreement

130,000,000

Acquired in process research and development expense

30,000,000

100,000,000

Payment for acquisition of equity interest

109,100,000

133,900,000

Percentage of investment (as a percent)

7.80%

12.20%

20.00%

Fair value of equity interest acquired

138,100,000

145,900,000

505,800,000

Change in fair value of investments

99,473,000

264,208,000

91,200,000

250,800,000

Cash payments to be made upon the achievement of certain regulatory and sales milestones

1,700,000,000

Number of indications in various territories as basis for estimation of milestone payments

Adjustment to goodwill from acquisition accounting for certain tax liabilities

2,989,000

3,000,000

Carrying amounts and classification of Alba's assets and liabilities included in consolidated balance sheet

Cash and cash equivalents

997,476,000

^[1]

997,476,000

^[1]

1,160,239,000

927,446,000

1,647,635,000

9,890,000

15,513,000

Other current assets

98,272,000

^[1]

98,272,000

^[1]

54,845,000

168,000

45,000

Property and equipment, net

507,152,000

^[1]

507,152,000

^[1]

502,856,000

18,000

4,000

Goodwill

866,272,000

^[1]

866,272,000

^[1]

822,071,000

2,118,000

493,091,000

486,619,000

Intangible assets

1,724,246,000

^[1]

1,724,246,000

^[1]

1,212,387,000

40,000,000

Current portion of long-term debt, net

3,560,000

Accounts payable

120,128,000

^[1]

120,128,000

^[1]

104,477,000

586,000

3,167,000

Accrued expenses

479,080,000

^[1]

479,080,000

^[1]

460,141,000

1,159,000

953,000

Noncontrolling Interest

$ 79,495,000

^[1]

$ 79,495,000

^[1]

$ 34,160,000

$ 29,797,000

$ 33,000,000

[1]	Amounts include assets and liabilities of our variable interest entities (VIEs). Our interests and obligations with respect to VIEs' assets and liabilities are limited to those accorded to us in our agreements with our VIEs. See Note 2 to these consolidated financial statements for amounts.

CEPHALON INC 10-Q